Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canadas Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYBs Acute Treatment of Migraine With or Without Aura in Cana
April 15, 2025 09:00 ET | Source: Scilex Holding Company ELYXYB® is…
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March…
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel,…
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
US Bankruptcy Court for the Southern District of Texas issued an order…